Post by
retiredcop on Jan 18, 2021 1:16pm
Impact on PMN
So we have two companies that have publically shown that their treatment for AD is working.to some extent. Yes the data is not overwhelming , the drugs are not perfect, but so far this has been the most positive news in at least 10 years . Here is a link to a reputable grooup and in this article a very important point is made ... this is what impacts PMN's future .... pretty clear. about what other companies need to hear inorder to push them to proceed in the same direction..
https://www.alzforum.org/news/research-news/phase-2-donanemab-curbs-cognitive-decline-early-alzheimers
It’s a good day for the field,” said Eric Siemers of Siemers Integration, LLC, who worked at Lilly when the trial began but has since retired. “We now have one more monoclonal antibody signaling in the right direction.”
Cynthia Lemere of Brigham and Women’s Hospital in Boston welcomed the news. “Lilly’s Phase 2 positive findings lend further support to the amyloid hypothesis and validate Aβ as a therapeutic target for early-stage AD,” she wrote (full comment below).
Comment by
BottomBroker on Jan 18, 2021 2:27pm
It would be nice if Promis could show that their treatment for AD is working.
Comment by
M101 on Jan 18, 2021 2:34pm
Agreed, and I'd like to see Elliot work this spin instead of Aducanumab alone.